Evidence map›Paper›PMID 27594517›Full record

ArticleSmall (Weinheim an der Bergstrasse, Germany)2016

A Size-Selective Intracellular Delivery Platform.

May Tun Saung, Armon Sharei, Viktor A Adalsteinsson, Nahyun Cho, Tushar Kamath, Camilo Ruiz, Jesse Kirkpatrick, Nehal Patel, Mari Mino-Kenudson, Sarah P Thayer and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Small (Weinheim an der Bergstrasse, Germany), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

May Tun SaungDepartment of Chemical Engineering, Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA, 02139, USA.
Armon ShareiDepartment of Chemical Engineering, Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA, 02139, USA.
Viktor A AdalsteinssonDepartment of Chemical Engineering, Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA, 02139, USA.
Nahyun ChoDepartment of Chemical Engineering, Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA, 02139, USA.
Tushar KamathDepartment of Chemical Engineering, Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA, 02139, USA.
Camilo RuizDepartment of Chemical Engineering, Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA, 02139, USA.
Jesse KirkpatrickDepartment of Chemical Engineering, Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA, 02139, USA.
Nehal PatelAdvanced Tissue Resources Core, Massachusetts General Hospital, Charlestown Navy Yard, Charlestown, MA, 02129, USA.
Mari Mino-KenudsonDepartment of Pathology, Massachusetts General Hospital, Boston, MA, 02114, USA.
Sarah P ThayerDepartment of Surgery, Massachusetts General Hospital, Boston, MA, 02114, USA.
Robert LangerDepartment of Chemical Engineering, Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA, 02139, USA.
Klavs F JensenDepartment of Chemical Engineering, Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA, 02139, USA.
Andrew S LissDepartment of Surgery, Massachusetts General Hospital, Boston, MA, 02114, USA.
J Christopher LoveDepartment of Chemical Engineering, Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA, 02139, USA.

Funding

VIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI MATTHEW G. VANDER HEIDEN · 1985 to 2026
$93.9M
The RAS and P13K Pathways in Pancreatic AdenocarcinomaP01CA117969 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DEPINHO, RONALD ANTHONY · 2006 to 2025
$41.7M
High throughput microfluidic intracellular delivery platformR01GM101420 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI ANDERSON, DANIEL G, JENSEN, KLAVS F · 2013 to 2016
$2.1M
National Cancer Institute P30-CA14051National Institutes of Health P01CA117969National Institutes of Health R01GM101420-01A1NCI NIH HHS P01 CA117969NCI NIH HHS P30 CA014051NIGMS NIH HHS R01 GM101420
6 · The paper itself

Abstract

Identifying and separating a subpopulation of cells from a heterogeneous mixture are essential elements of biological research. Current approaches require detailed knowledge of unique cell surface properties of the target cell population. A method is described that exploits size differences of cells to facilitate selective intracellular delivery using a high throughput microfluidic device. Cells traversing a constriction within this device undergo a transient disruption of the cell membrane that allows for cytoplasmic delivery of cargo. Unique constriction widths allow for optimization of delivery to cells of different sizes. For example, a 4 μm wide constriction is effective for delivery of cargo to primary human T-cells that have an average diameter of 6.7 μm. In contrast, a 6 or 7 μm wide constriction is best for large pancreatic cancer cell lines BxPc3 (10.8 μm) and PANC-1 (12.3 μm). These small differences in cell diameter are sufficient to allow for selective delivery of cargo to pancreatic cancer cells within a heterogeneous mixture containing T-cells. The application of this approach is demonstrated by selectively delivering dextran-conjugated fluorophores to circulating tumor cells in patient blood allowing for their subsequent isolation and genomic characterization.

Indexed as

circulating tumor cellsintracellular deliverymicrofluidicssize-selective delivery

Identifiers

PMID27594517
PMCPMC5337179

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.